Arkolith/Insider Trading/AMRX/Form 4

Konidaris Tasos

Executive Vice President & CFOAmneal Pharmaceuticals, Inc. (AMRX) · full profile →Form 4 · filed Mar 5, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
15
10 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 4, 2026Option exercise(M)44K——471K
Mar 4, 2026Tax withholding(F)22K$13.30$293K449K
Mar 3, 2026Tax withholding(F)24K$13.31$323K184K
Mar 3, 2026Option exercise(M)29K——213K
Mar 3, 2026Tax withholding(F)14K$13.31$190K199K
Mar 3, 2026Tax withholding(F)230K$13.31$3.1M427K
Mar 3, 2026Option exercise(M)45K——167K
Mar 3, 2026Option exercise(M)459K——657K
Mar 3, 2026Tax withholding(F)16K$13.31$215K151K
Mar 3, 2026Option exercise(M)57K——209K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 4, 2026Option exercise(M)50K—$088K
Mar 3, 2026Option exercise(M)45K—$00
Mar 3, 2026Option exercise(M)57K—$057K
Mar 3, 2026Option exercise(M)29K—$086K
Mar 3, 2026Option exercise(M)459K—$00

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-015239) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML